Specify a stock or a cryptocurrency in the search bar to get a summary
Acasti Pharma Inc
ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. Address: 103 Carnegie Center, Princeton, NJ, United States, 08540
Analytics
WallStreet Target Price
5.99 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACST
Dividend Analytics ACST
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACST
Stock Valuation ACST
Financials ACST
Results | 2019 | Dynamics |